Artiva Biotherapeutics Inc (ARTV)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$6.15-0.81%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Artiva Biotherapeutics Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.592
Annual ending 2026-12-31
Revenue	—	0
EPS	—	-2.594
Annual ending 2027-12-31
Revenue	—	0
EPS	—	-2.704

Management figures unavailable.

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
ATM stock offering remains suspended	A supporting condition in Artiva Biotherapeutics Inc's published investment case. The stated target is ATM offering suspended until new prospectus filed.	Intact	ATM offering resumes without clear need	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Stable leadership and insider confidence	A supporting condition in Artiva Biotherapeutics Inc's published investment case. The stated target is No further significant insider stock sales.	Under Pressure	continued insider selling over next 12 months	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
FDA RMAT designation and clinical data milestones	FDA gave RMAT status.	Intact	clinical data not shared by mid-2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Revenue reaches about $108 million	A primary condition in Artiva Biotherapeutics Inc's published investment case. The stated target is about $108 million.	Intact	revenue falls below $50 million by mid-2027	Revenue: $0 FY2026-Q2; GAAP. Published target: about $108 million. Target period ends 2027-06-30; this observation covers 2026-Q2. Source published Aug 6, 20260 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-2.70

Unavailable → $-2.70 · observed estimates

FY2027 revenueUnavailable

$0.00B → Unavailable · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	$0	4 / 6
2026-07-25	Unavailable	$0	4 / 6
2026-07-26	Unavailable	$0	4 / 6
2026-07-27	Unavailable	Unavailable	4 / 0
2026-07-28	Unavailable	$0	4 / 6
2026-07-29	Unavailable	$0	4 / 6
2026-07-30	Unavailable	$0	4 / 6
2026-07-31	Unavailable	$0	4 / 6
2026-08-01	Unavailable	$0	4 / 6
2026-08-02	Unavailable	$0	4 / 6
2026-08-03	Unavailable	$0	4 / 6
2026-08-04	Unavailable	$0	4 / 6
2026-08-05	Unavailable	$0	4 / 6
2026-08-06	Unavailable	$0	4 / 6
2026-08-07	Unavailable	Unavailable	4 / 0
2026-08-08	Unavailable	$0	4 / 6
2026-08-09	Unavailable	$0	4 / 6
2026-08-10	Unavailable	$0	4 / 6
2026-08-11	$-2.61	$0	5 / 6
2026-08-12	$-2.61	$0	5 / 6
2026-08-13	$-2.61	$0	5 / 6
2026-08-14	Unavailable	Unavailable	4 / 0
2026-08-15	Unavailable	Unavailable	4 / 0
2026-08-16	$-2.91	Unavailable	5 / 0
2026-08-17	$-2.91	Unavailable	5 / 0
2026-08-18	$-2.91	Unavailable	5 / 0
2026-08-19	$-2.91	Unavailable	5 / 0
2026-08-20	$-2.70	Unavailable	5 / 0
2026-08-21	$-2.70	Unavailable	5 / 0
2026-08-22	$-2.70	Unavailable	5 / 0
2026-08-23	$-2.70	Unavailable	5 / 0
2026-08-24	$-2.70	Unavailable	5 / 0
2026-08-25	$-2.70	Unavailable	5 / 0
2026-08-26	$-2.70	Unavailable	5 / 0
2026-08-27	$-2.70	Unavailable	5 / 0
2026-08-28	$-2.70	Unavailable	5 / 0
2026-08-29	$-2.70	Unavailable	5 / 0
2026-08-30	$-2.70	Unavailable	5 / 0
2026-08-31	$-2.70	Unavailable	5 / 0
2026-09-01	$-2.70	Unavailable	5 / 0
2026-09-02	$-2.70	Unavailable	5 / 0
2026-09-03	$-2.70	Unavailable	5 / 0
2026-09-04	$-2.70	Unavailable	5 / 0
2026-09-05	$-2.70	Unavailable	5 / 0
2026-09-06	$-2.70	Unavailable	5 / 0
2026-09-07	$-2.70	Unavailable	5 / 0
2026-09-08	$-2.70	Unavailable	5 / 0
2026-09-09	$-2.70	Unavailable	5 / 0
2026-09-10	$-2.70	Unavailable	5 / 0
2026-09-11	$-2.70	Unavailable	5 / 0
2026-09-12	$-2.70	Unavailable	5 / 0
2026-09-13	$-2.70	Unavailable	5 / 0
2026-09-14	$-2.70	Unavailable	5 / 0
2026-09-15	$-2.70	Unavailable	5 / 0
2026-09-16	$-2.70	Unavailable	5 / 0
2026-09-17	$-2.70	Unavailable	5 / 0
2026-09-18	$-2.70	Unavailable	5 / 0
2026-09-19	$-2.70	Unavailable	5 / 0
2026-09-20	$-2.70	Unavailable	5 / 0
2026-09-21	$-2.70	Unavailable	5 / 0
2026-09-22	$-2.70	Unavailable	5 / 0
2026-09-23	$-2.70	Unavailable	5 / 0
2026-09-24	$-2.70	Unavailable	5 / 0
2026-09-25	$-2.70	Unavailable	5 / 0
2026-09-26	$-2.70	Unavailable	5 / 0
2026-09-27	$-2.70	Unavailable	5 / 0
2026-09-28	$-2.70	Unavailable	5 / 0
2026-09-29	$-2.70	Unavailable	5 / 0
2026-09-30	$-2.70	Unavailable	5 / 0
2026-10-01	$-2.70	Unavailable	5 / 0
2026-10-02	$-2.70	Unavailable	5 / 0
2026-10-03	$-2.70	Unavailable	5 / 0
2026-10-04	$-2.70	Unavailable	5 / 0
2026-10-05	$-2.70	Unavailable	5 / 0
2026-10-06	$-2.70	Unavailable	5 / 0
2026-10-07	$-2.70	Unavailable	5 / 0
2026-10-08	$-2.70	Unavailable	5 / 0
2026-10-09	$-2.70	Unavailable	5 / 0
2026-10-10	$-2.70	Unavailable	5 / 0
2026-10-11	$-2.70	Unavailable	5 / 0
2026-10-12	$-2.70	Unavailable	5 / 0
2026-10-13	$-2.70	Unavailable	5 / 0
2026-10-14	$-2.70	Unavailable	5 / 0
2026-10-15	$-2.70	Unavailable	5 / 0
2026-10-16	$-2.70	Unavailable	5 / 0
2026-10-17	$-2.70	Unavailable	5 / 0
2026-10-18	$-2.70	Unavailable	5 / 0
2026-10-19	$-2.70	Unavailable	5 / 0
2026-10-20	$-2.70	Unavailable	5 / 0
2026-10-21	$-2.70	Unavailable	5 / 0
2026-10-22	$-2.70	Unavailable	5 / 0
2026-10-23	$-2.70	Unavailable	5 / 0
2026-10-24	$-2.70	Unavailable	5 / 0

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	6	0	0
2026-06-01	6	0	0
2026-07-01	6	0	0
2026-08-01	6	0	0
2026-09-01	6	0	0
2026-10-01	6	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 6 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

ATM stock offering remains suspendedDirect metric needs a verified mapping
Stable leadership and insider confidencePublished status: Under Pressure
FDA RMAT designation and clinical data milestonesDirect metric needs a verified mapping
Revenue reaches about $108 millionRevenue: $0

Next proof point

Nov 11, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.5%Typical daily move · historical

Downside history

-56.3%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Artiva Biotherapeutics Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a high-risk clinical development business, not an established earnings compounder, and it is currently loss-making. Its multi-year view is in a watch state: AlloNK progress and a longer cash runway are constructive, but recent financial performance is weak relative to its industry cohort.

What's priced into Artiva Biotherapeutics Inc

ARTV is described as cheap versus peers, but the evidence snapshot does not specify the market’s exact expectations. Fragility is rated low, though that does not remove the uncertainty tied to its losses, high risk, and weak recent performance.

What the fundamentals likely do

Near term, results carry meaningful miss risk, with a 45% estimated miss probability and recent peer misses cited as a concern. Management has extended the stated cash runway to 2029 and presented AlloNK data, while the planned Phase 3 trial in refractory RA remains a key execution step for the multi-year thesis.

What Artiva Biotherapeutics Inc hinges on

The thesis depends on starting the planned Phase 3 trial in the second half of 2026 and continuing to show useful clinical progress with AlloNK. Near-term risks include a guidance cut and weaker jobs data, while continued earnings strength and higher guidance from healthcare bellwethers could support the sector backdrop.